Search

Your search keyword '"Tobe, Sheldon"' showing total 867 results

Search Constraints

Start Over You searched for: Author "Tobe, Sheldon" Remove constraint Author: "Tobe, Sheldon"
867 results on '"Tobe, Sheldon"'

Search Results

53. Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions)

56. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

58. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function

61. The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy

63. Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary)

64. Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group

65. Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline

66. Abstract 52: KDIGO (Kidney Disease: Improving Global Outcomes) Guideline Update On The Management Of Blood Pressure In Chronic Kidney Disease: What’s New And What’s Different From Other Guidelines

67. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

69. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy

70. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I – blood pressure measurement, diagnosis and assessment of risk

73. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update

74. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk

77. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy

81. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy

82. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk

86. A retrospective observational population‐based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m 2 in Ontario, Canada

87. Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

88. Supplemental_Figure_1 – Supplemental material for An Interprofessional Approach in Caring for a Patient on Maintenance Hemodialysis with COVID-19 in Toronto, Canada: An Educational Case Report

89. The Global Alliance for Chronic Diseases Hypertension Program

94. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk

95. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy

97. Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

Catalog

Books, media, physical & digital resources